Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy

  • Ken Suzawa
  • Junichi Soh
  • Yuta Takahashi
  • Hiroki Sato
  • Kazuhiko Shien
  • Hiromasa Yamamoto
  • Susumu Kanazawa
  • Katsuyuki Kiura
  • Shinichiro Miyoshi
  • Shinichi ToyookaEmail author
Original Article



The purpose of this study was to review the clinical course of patients with recurrence after induction chemoradiotherapy followed by surgery (trimodality therapy) for locally advanced non-small cell lung cancer (LA-NSCLC) and to identify the factors associated with favorable clinical outcome after recurrence.


We analyzed the records of 140 patients with LA-NSCLC who were treated with trimodality therapy between 1999 and 2014.


Recurrence developed after trimodality therapy in 48 patients. A yp-N positive status was associated with a high risk of recurrence (HR, 2.05; P = 0.048). Of the 45 of these patients able to be assessed retrospectively, 18 had oligometastatic recurrence and 20 underwent local treatment with curative intent. Local treatment was most frequently given to patients with oligometastatic recurrence (P < 0.001). The median post-recurrence survival (PRS) was 41.4 months, and the 2-year PRS rate was 62%. Patients who received local treatment showed better PRS (P = 0.009). The presence of liver metastasis (P = 0.008), bone metastasis (P = 0.041), or dissemination (P < 0.0001) were associated with worse PRS.


The survival of patients who received aggressive local treatment for postoperative recurrence after trimodality therapy for LA-NSCLC was better than that of patients who did not.


Lung cancer Induction chemoradiotherapy Oligometastasis Oligorecurrence Local treatment 




Compliance with ethical standards

Conflict of interest

S. Toyooka had honorarium and grants and endowments from Taiho Pharmaceutical Co., Ltd. K. Kiura had honorarium, grants and endowments from Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd, and Nippon Boehringer Ingelheim Co., Ltd. No other authors have any conflicts of interest to declare.


  1. 1.
    Group, NSCLC Meta-analysis Collaborative. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561–71.CrossRefGoogle Scholar
  2. 2.
    Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.CrossRefGoogle Scholar
  3. 3.
    Lococo F, Cesario A, Margaritora S, Dall’Armi V, Nachira D, Cusumano G, et al. Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results. Ann Thorac Surg. 2012;93:1633–40.CrossRefGoogle Scholar
  4. 4.
    Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, et al. Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol. 2012;19:2685–92.CrossRefGoogle Scholar
  5. 5.
    Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;14:565–9.CrossRefGoogle Scholar
  6. 6.
    Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M, et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer. 2004;90:979–84.CrossRefGoogle Scholar
  7. 7.
    Toyooka S, Kiura K, Shien K, Katsui K, Hotta K, Kanazawa S, et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;15:954–60.CrossRefGoogle Scholar
  8. 8.
    Sato H, Toyooka S, Soh J, Hotta K, Katsui K, Yamamoto H, et al. The feasibility of median sternotomy with or without thoracotomy for locally advanced non-small cell lung cancer treated with induction chemoradiotherapy. Ann Thorac Surg. 2016;102:985–992.CrossRefGoogle Scholar
  9. 9.
    Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefGoogle Scholar
  10. 10.
    Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82:197–203.CrossRefGoogle Scholar
  11. 11.
    Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med. 2012;2012:396592.CrossRefGoogle Scholar
  12. 12.
    De Ruysscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol. 2012;7:1547–55.CrossRefGoogle Scholar
  13. 13.
    Congedo MT, Cesario A, Lococo F, De Waure C, Apolone G, Meacci E, et al. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience. J Thorac Cardiovasc Surg. 2012;144:444–52.CrossRefGoogle Scholar
  14. 14.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRefGoogle Scholar
  15. 15.
    Endo C, Hasumi T, Matsumura Y, Sato N, Deguchi H, Oizumi H, et al. A prospective study of surgical procedures for patients with oligometastatic non-small cell lung cancer. Ann Thorac Surg. 2014;98:258–64.CrossRefGoogle Scholar
  16. 16.
    Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008;26:1142–7.CrossRefGoogle Scholar
  17. 17.
    Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg. 2001;122:548–53.CrossRefGoogle Scholar
  18. 18.
    Furak J, Trojan I, Szoke T, Agocs L, Csekeo A, Kas J, et al. Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg. 2005;79:241–7 (discussion—7).CrossRefGoogle Scholar
  19. 19.
    Raz DJ, Lanuti M, Gaissert HC, Wright CD, Mathisen DJ, Wain JC. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg. 2011;92:1788–92 (discussion 93).CrossRefGoogle Scholar
  20. 20.
    Suzuki H, Yoshino I. Approach for oligometastasis in non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2016;64:192–6.CrossRefGoogle Scholar
  21. 21.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.CrossRefGoogle Scholar
  22. 22.
    Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. 2012;75:9–14.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Ken Suzawa
    • 1
  • Junichi Soh
    • 1
  • Yuta Takahashi
    • 1
  • Hiroki Sato
    • 1
  • Kazuhiko Shien
    • 1
  • Hiromasa Yamamoto
    • 1
  • Susumu Kanazawa
    • 2
  • Katsuyuki Kiura
    • 3
  • Shinichiro Miyoshi
    • 1
  • Shinichi Toyooka
    • 1
    Email author
  1. 1.Department of Thoracic SurgeryOkayama University HospitalOkayamaJapan
  2. 2.Department of RadiologyOkayama University HospitalOkayamaJapan
  3. 3.Department of Respiratory MedicineOkayama University HospitalOkayamaJapan

Personalised recommendations